{"id":"NCT00402831","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"ProQuad® Intramuscular vs Subcutaneous","officialTitle":"An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10-06","primaryCompletion":"2007-05-11","completion":"2007-05-11","firstPosted":"2006-11-22","resultsPosted":"2018-08-13","lastUpdate":"2018-08-13"},"enrollment":405,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Measles","Mumps","Rubella","Varicella"],"interventions":[{"type":"BIOLOGICAL","name":"ProQuad®","otherNames":[]}],"arms":[{"label":"Intramuscular ProQuad®","type":"EXPERIMENTAL"},{"label":"Subcutaneous ProQuad®","type":"ACTIVE_COMPARATOR"}],"summary":"Primary objective:\n\nTo demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in terms of antibody response rates to measles, mumps, rubella and to varicella at 42 days following the second dose of ProQuad®\n\nSecondary objectives:\n\n* To describe the antibody response rates to measles, mumps, rubella and varicella measured 30 days following the first dose of ProQuad® administered by IM or SC route,\n* To describe the antibody titres to measles, mumps, rubella and varicella at 30 days following the first dose and at 42 days following the second dose of ProQuad® both administered by IM or SC route,\n* To describe the safety profile of two doses of ProQuad® both administered by IM or SC route.","primaryOutcome":{"measure":"Percentage of Participants Meeting Antibody Response Rate Criteria Six Weeks After Completing ProQuad® Treatment","timeFrame":"Week 10 (6 weeks after Dose 2 on Week 4)","effectByArm":[{"arm":"Intramuscular ProQuad®","deltaMin":100,"sd":null},{"arm":"Subcutaneous ProQuad®","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["30481110"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":202},"commonTop":["Pyrexia","Injection site erythema","Ear infection","Injection site pain","Nasopharyngitis"]}}